Takeda, Snow Myeloma App ‘Being Patient’ Wins Pharma Choice Award

Takeda, Snow Myeloma App ‘Being Patient’ Wins Pharma Choice Award
0
(0)

Takeda and Snow Companies won one of the top prizes in PM360’s annual Pharma Choice Awards for an app aimed at promoting understanding of what life with multiple myeloma is like.

PM360, a health marketing industry trade magazine, gives the awards each year for the best healthcare campaigns and initiatives across 15 categories.

Takeda’s global oncology patient advocacy program, along with patient engagement agency Snow, received a gold award in the app category for “Being Patient: Multiple Myeloma,” which uses activities, videos and more to illustrate the experience of a multiple myeloma patient.

Takeda said it designed the interactive app to give employees a deeper sense of patients’ emotional, financial, psychosocial, and physical experiences.

“This transformative experience serves as a driving force and reminder that patients remain at the core of all business decisions, no matter what role you serve at Takeda,” the company on a PM360 webpage describing the app.

“Being Patient: Multiple Myeloma” allows users to see what patients’ everyday lives are like. The app, which runs on the Android operating system, goes through a series of experiences starting from diagnosis. A journaling feature allows users to document thoughts and feelings throughout the experience. The app includes story narration and educational videos, as well as images from actual patients.

Guided activities emulate experiences associated with myeloma, a cancer characterized by anemia, fatigue, bleeding and bruising, and a risk of infection. One activity uses shoe inserts to simulate what it’s like dealing with peripheral neuropathy, nerve damage that is a common side effect of treatment for multiple myeloma.

In another section, the user is told: “Finally, after four days, enough stem cells are removed and the process is over. You are then admitted to the hospital and given high-dose chemotherapy overnight, destroying all your bone marrow. Over the next two weeks, you are in reverse isolation, meaning you must take every precaution against acquiring germs and getting sick.”

“Being Patient: Multiple Myeloma” is part of Takeda’s global oncology patient advocacy program, which helps cancer communities access care, delivers education about specific cancers, and seeks to influence policy on patients’ behalf. It also leads several advocacy and awareness programs and activities.

The 45 Pharma Choice winners are highlighted in the current issue of PM360. Gold, silver and bronze awards go to the top three vote-getters in each of the 15 categories. Winners were selected by PM360 readers — most of them pharmaceutical marketers — who cast more than 7,000 online votes based on content, format, imagination, industry influence and overall quality.

“The best judge for whether a campaign is creative, clever or award-worthy is someone who knows what goes into crafting a campaign and what it takes to make it great, so what better way to decide the year’s best creative than giving the thousands of people who do that work a chance to cast their vote,” Anna Stashower, PM360 CEO and publisher, said in a press release. “We congratulate all of this year’s winners, and are happy to present then both with a trophy and the knowledge that their peers place them at the top of all campaigns for the past year.”

Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”
Total Posts: 145
Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
×
Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”
Latest Posts
  • Stand Up to Cancer
  • HealthTree, new feature
  • Leukemia & Lymphoma Society
  • HealthTree University opens

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?